Organ Transplant Rejection Medication Market - By Drug Class (Calcineurin Inhibitor, Antibodies, Antiproliferative Agent), Transplant Type (Kidney, Liver, Heart), Distribution Channel (Hospital, Retail Pharmacies), Global Forecast, 2023-2032
Published Date: July - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationOrgan Transplant Rejection Medication Market - By Drug Class (Calcineurin Inhibitor, Antibodies, Antiproliferative Agent), Transplant Type (Kidney, Liver, Heart), Distribution Channel (Hospital, Retail Pharmacies), Global Forecast, 2023-2032
Organ Transplant Rejection Medication Market Size
Organ Transplant Rejection Medication Market size in 2022 was valued at USD 5.5 billion and is expected to witness growth at CAGR of 3.2% and reach USD 7.5 billion by 2032. The factors driving the growth of global organ transplant rejection medication includes increasing organ transplant procedures due to chronic diseases and technological advancements in organ transplantation and tissue engineering.
Organ transplant rejection refers to the immune response of a recipient's body against a transplanted organ or tissue, considering it as foreign and attempting to destroy it. The organ transplant rejection medications also known as immunosuppressive medications or immunosuppressants, are drugs used to suppress this immune response and allow the transplanted organ to function properly within the recipient's body.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Organ Transplant Rejection Medication Market Size in 2022 | USD 5.5 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 3.2% |
| 2032 Value Projection | USD 7.5 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 120 |
| Tables, Charts & Figures | 226 |
| Segments covered | Drug Class, Transplant Type, Distribution Channel, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
The pandemic put a huge strain on hospitals and clinics. They had to shift their focus to treating COVID-19 patients, which left less room for other medical procedures. This meant that many non-urgent surgeries, like organ transplants, had to be postponed. Getting the organs themselves became harder too. There were fewer ways to transport them, and it became riskier to do so. Plus, the factories that made the drugs and materials needed for transplants were also affected by the pandemic. This led to shortages and delays. People who have had organ transplants need to take special medicines to prevent their bodies from rejecting the new organ. But with so much focus on COVID-19, it became harder for them to get regular check-ups and refills. This could have put their health at risk.
Organ Transplant Rejection Medication Market Driving & Restraining Factors
The increasing organ transplant procedures due to chronic diseases and technological advancements in organ transplantation and tissue engineering are the major factors driving the growth of the global market. The increasing prevalence of end-stage organ diseases and improved patient outcomes have increased the demand of organ transplant procedures. Due to the increasing number of transplants the demand for rejection medications is also growing.
The restraining factors of the global market are high cost of organ transplantation procedures and low availability of organs for transplantation. The cost of organ transplantation procedures is high, and the lifelong use of immunosuppressive medications can result in significant financial burden on patients.
Organ Transplant Rejection Medication Market Analysis
Imagine you're getting a new organ transplant, like a heart or kidney. To keep your body from rejecting the new organ, you'll need to take some powerful medicines. One type of medicine is called "calcineurin inhibitors." Think of them as superheroes that protect your new organ from bad cells trying to attack and reject it. In fact, they make up about 36% of the market for transplant rejection medicines. The reason they're so popular is because of two famous heroesPrograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). They're like Superman and Wonder Woman for your transplant! They prevent serious problems that could damage your new organ, even months or years after the surgery. Plus, calcineurin inhibitors can be your long-term buddies, helping you maintain your new organ's health over time. Whether you need them by mouth or through a vein, they've got you covered!
Based on transplant type, the organ transplant rejection medicine market is classified into kidney, liver, heart, lung, pancreas, and other transplant types. The kidney segment is expected to grow at CAGR of 3.3% during the forecast period. Kidneys are highly immunogenic organs to which immune systems are more likely to recognize and respond to them as foreign. This can result in a stronger immune response and a higher risk of rejection. Additionally, the number of patients with kidney transplant are increasing globally. For, instance, United Network of Organ Sharing, on an average, 68 people received a new kidney each day in 2021. Kidney transplants are more cost-effective compared to dialysis and people with kidney failure gets an opportunity to live without extended period of dialysis.
Based on the distribution channel, the organ transplant rejection medicine market is segmented into hospital, retail, and online pharmacies. The hospital pharmacies segment held highest market share of 61.6%. Hospital pharmacies are commonly used for dispensing and managing organ transplant rejection medications. The hospital pharmacies offer easy and rapid access to such medications for the hospitalized patients. The retail pharmacies accounted for second highest market share due to the availability of various organ transplant rejection medications, whereas the online pharmacies segment is expected to grow at fastest growth rate due to convenience and accessibility of purchasing such medicines.
The North America organ transplant rejection medicine market was valued to be USD 2.4 billion in 2022. The well-developed healthcare systems, advanced healthcare infrastructure, increasing healthcare expenditure, increasing prevalence of chronic diseases, increasing research and development, and presence of key players operating are some of the factors boosting the growth of this market. During the forecast period, Asia Pacific organ transplant rejection market is expected to grow due to the increasing number of organ transplant, increasing prevalence of chronic diseases, increased research and development of novel immunosupppressants, and expansion of key players.
Organ Transplant Rejection Medication Market Share
The key players in the organ transplant rejection medicine market are
- Astellas Pharma Inc.
- Sanofi
- Bristol-Myers Squibb Company
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Accord Healthcare Ltd
- Viatris, Inc.
- Dr. Reddy's Laboratories Ltd
- Veloxis Pharmaceuticals A/S
- GlaxoSmithKline plc.
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
Organ Transplant Rejection Medication Industry News
- In July 2021, US FDA approved Astellas Pharma’s supplemental new drug application (sNDA) for PROGRAF (tacrolimus) for the preventing the organ rejection in adult and pediatric with lung transplant. This product launch helped the company to enhance their product portfolio and their revenue.
- In February 2023, Sirolimus tablets of Zydus received US FDA approval for organ rejection in transplant recipients. This product approval will help the company to strengthen its product portfolio and boost the revenue of the company.
The organ transplant rejection medication market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
Market Size, By Drug Class
- Calcineurin inhibitors
- Antibodies
- Antiproliferative agents
- mTOR inhibitor
- Steroids
Market Size, By Transplant Type
- Kidney
- Liver
- Heart
- Lung
- Pancreas
- Other transplant types
Market Size, By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Switzerland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy